Print

Purpose

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Age ≥ 18 years. 2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI. 3. Ability to understand a written informed consent document, and the willingness to sign it. 4. Diagnosis of metastatic cancer.

Exclusion Criteria

  1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation. 2. Individuals with contraindications to MRI. This will be determined through review of the UCSF MRI screening form by qualified site personnel

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Whole Body DWI plus FDG PET/MRI 		Participants will receive 5 to 10 Megabecquerel (MBq) +/- 10% of 18F-fluorodeoxyglucose as an intravenous injection and undergo a FDG PET/MRI scan that will extend from the vertex to the mid-thighs. Imaging will be performed from vertex to mid-thighs using standard protocol. Participants may also obtain an optional second FDG PET/MRI with DWI within 6 months.
  • Drug: Fluorodeoxyglucose F18
    Given IV as part of routine imaging
    Other names:
    • Fludeoxyglucose F18 (FDG)
    • 2-deoxy-2-[fluorine-18]fluoro-D-glucose
    • Fluorodeoxyglucose
  • Procedure: Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)
    Imaging procedure
    Other names:
    • PET/MRI
  • Procedure: Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)
    Imaging procedure done concurrently with PET/MRI
    Other names:
    • WB-MRI-DWI
  • Device: General Electric (GE) SIGNA PET/MR
    Imaging device
    Other names:
    • GE SIGNA PET/MR
    • SIGNA PET/MR

Recruiting Locations

University of California, San Francisco
San Francisco, California 94143
Contact:
Brad Kline
Brad.Kline@ucsf.edu

More Details

Status
Recruiting
Sponsor
University of California, San Francisco

Study Contact

Brad Kline
877-827-3222
brad.kline@ucsf.edu

Detailed Description

PRIMARY OBJECTIVE: I. Correlation of DWI and FDG to detect disease. SECONDARY OBJECTIVE: I. Inter-reader variability of DWI interpretation by region. OUTLINE: Participants will be imaged at a single timepoint using whole body DWI concurrent with FDG PET/MRI within 60 days of receiving a non-FDG PET (either PET/CT or PET/MRI). There will be an optional PET/MRI performed within six months of the original study. Participants will be followed up through a medical records review for up to two years.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.